Two Onc Docs shared a post on X/Twitter:
”Discussing the practice changing LAURA trial for stage 3 unresectable NSCLC for patients with EGFRm with the expert himself Suresh S. Ramalingam including:
- Why placebo control.
- Expected OS.
- Why indefinite treatment.
- Role for other driver mutations.”
Source: Two Onc Docs/X